Beijing Wantai Biological Pharmaceutical Co., Ltd. (unlisted subsidiary, hereinafter referred to as "Wantai Co., Ltd.") was established in 2023 as a wholly-owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., Ltd. (listed parent). It is an innovative vaccine company integrating R&D and industrialization, focusing on the research, development and industrialization of viral vaccines for intestinal and respiratory diseases.

Relying on independent and collaborative R&D, Wantai Co., Ltd. has established in-depth partnerships with scientific research institutions such as Xiamen University and the University of Hong Kong, creating an integrated vaccine innovation R&D model that combines industry, academia and research. Among them, the world's first intranasal influenza virus vector COVID-19 vaccine has obtained emergency use authorization in China, and the company owns 23 invention patents.